Transdermal rivastigmine patch in outpatient services in Austria: A naturalistic study in 103 patients with Alzheimer dementia;Rivastigmin-pflaster in der ambulanten versorgung in Österreich: Eine naturalistische studie an 103 patientinnen mit Alzheimer demenz

Neuropsychiatrie

Volumn 23, Issue 1, 2009, Pages 58-63

  Schmidt, Reinhold ^a   Alf, Claude ^b   Bancher, Christian ^c   Benke, Thomas ^d   Berek, Klaus ^e   Dal Bianco, Peter ^e   Führwürth, Gerhard ^f   Imarhiagbe, Douglas ^g   Jagsch, Christian ^h   Lechner, Anita ^a   Rainer, Michael ⁱ   Reisecker, Franz ^j   Rotaru, Juliana ^k   Uranüs, Margarete ^l   Walter, Andreas ^g   Winkler, Andreas ^m   Wuschitz, Albert ⁿ  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b 1 Neurologische Abteilung   (Austria)

^c Landesklinikum Waldviertel Horn   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Krankenhaus der Barmherzigen Brüder Eisenstadt   (Germany)

^g Sozialpsychiatrische Abteilung ^*

^h Psychiatrische Klinik Wels   (Austria)

ⁱ DANUBE HOSPITAL   (Austria)

^j KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^k KEPLER UNIVERSITY HOSPITAL   (Austria)

^l Landesnervenklinik Sigmund Freud Graz   (Germany)

^m Haus der Barmherzigkeit   (Austria)

ⁿ Wallensteinplatz   (Austria)

more..

Author keywords

Alzheimer's disease; Clinical routine; Rivastigmine; Therapy

Indexed keywords

RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; AUSTRIA; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; OPEN STUDY; OUTPATIENT CARE; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; FEMALE; FOLLOW UP; INTRADERMAL DRUG ADMINISTRATION; MALE; MENTAL HEALTH; MULTICENTER STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 66149089567     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Birks J Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.
2. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-397 (Pubitemid 46627453)
3. Alf C, Bancher C.), Benke T, Berek K.,Bodner, T, Croy, A, Dal-Bianco P. Fischer P,Fruhwuerth G.,Gatterer G, Grossmann, J Hinterhuber H, Imarhiagbe, D.), Jaksch A, Jellinger K, Kalousek M, Kapeller P, Krautgartner M, Ladurner G, Leblhuber F, Lechner A, Lingg A, Marksteiner J, Nakajima T, Psota G Rainer M, Ransmayr G, Reisecker F, Schmidt R, Spatt J, Walch T, Walter A, Wancata J, Winkler A. Consensus statements "Dementia" of the Austrian Alzheimer Society - Update 2006; Neuropsychiatrie 2006; 20: 221-231
4. Alf C, Bancher C, Benke T, Berek K, Dal-Bianco P, Fischer P, Fruhwürth G, Gatterer G, Hinterhuber H, Jellinger K, Kalousek M, Kapeller P, Leblhuber F, Marksteiner J, Psota G, Rainer M, Ransmayr G, Schmidt R, Walch T, Walter A, Wancata J. Recommendations of NICE for treatment of the Alzheimer's disease: Comments of the Austrian Alzheimer Society. Neuropsychiatrie 2006; 20: 137-139 (Pubitemid 44146836)
5. Schmidt R, Assem-Hilger E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Stodie;gmann E, Wancata J, Wehringer C. Geschlechtsspezifische Unterschiede der Alzheimer Demenz. Neuropsychiatrie 2008; 22: 1-15
6. Ransmayr G, Katzenschlager R, Dal-Bianco P, Wenning G, Bancher C, Jellinger K, Schmidt R, Poewe W. Lewy-Körper Demenz und ihre differentialdiagnostische Abgrenzung von Alzheimer'scher Erkrankung. Neuropsychiatrie 2007; 21: 63-74 (Pubitemid 47049605)
7. Mercier F, Lefevre G, Huang H-L A, Schidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by transdermal patch versus capsules. Curr Med Res Opin 2007; 23:3199-3204
8. Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R. IDEAL. A 6-month. Double-blind, placebo- controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69 (suppl1): S14-S22.
9. Conato J. Observational Versus Experimental Studies: What's the Evidence for a Hierarchy? NeuroRx 2004; 1: 341-347
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-949 (Pubitemid 14076461)
11. Folstein M, S. Folstein S, et al. (1975). "Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician." J Psychiatr Res 12: 189-198
12. Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria Int Clin Psychopharmacol 2002; 17: 81-85
13. Cummings J, Lefevre G, Small G, Appel- Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69 (suppl 1): S10-S13. (Pubitemid 47205654)
14. Persönliche Kommunkation Exelon Patch Advisory Board Meeting, December 4th, 2008; Berlin, Germany.
15. Winblad B, Cummings J, Andeasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-467 (Pubitemid 46831690)
16. Behl P, Stefurak TL, Black SE. Cognitive Markers of Progression in Alzheimer's disease. Can J Neurol Sci 2005; 32:140-151